Aegerion aims for $68m to fund Juxtapid launch
This article was originally published in Scrip
Aegerion Therapeutics is aiming to raise net proceeds of $67.9 million in a public offering that it expects to close this week. The firm is seeking cash to fund the commercial launch of Juxtapid (lomitapide), its first product, which received FDA approval as a treatment for patients with the rare genetic disease homozygous familial hypercholesterolemia (HoFH) last month.
You may also be interested in...
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.
INFOGRAPHIC: A snapshot of the compensation packages granted to the chiefs of the world’s biggest pharma companies, along with key performance stats for the businesses they lead.